Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03086278 | A Study of AST-008 in Healthy Subjects | PHASE1 | COMPLETED | 16 | — | — | Oct 20, 2017 | Aug 16, 2018 | Sep 25, 2018 | 1 | United Kingdom |
To evaluate SAEs after a single subcutaneous dose of AST-008
To evaluate adverse events after a single subcutaneous dose of AST-008
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AST-008 | DRUG | AST-008 is a toll-like receptor 9 agonist. |
Main Inclusion Criteria: 1. Healthy male or female subjects aged ≥18 and ≤40 years of age at the time of first dosing. 2. Subjects must have a body mass index (BMI) between 18.0-25.0 kg/m² inclusive. 3. Satisfactory medical assessment with no clinically significant or relevant abnormalities as dete...